Medicare Spending Implications for Semaglutide Under Voluntary Price Agreements
This study compares expected total Medicare spending on semaglutide in 2027 under voluntary price agreement participation vs nonparticipation and estimates beneficiaries eligible for expanded obesity-indication coverage whose treatment costs could be offset with savings from the agreement.
Authors
- Ashley A. Leech (ORCID: https://orcid.org/0000-0001-6795-929X)
- Jinyi Zhu (ORCID: https://orcid.org/0000-0001-8169-5956)
- Stacie B. Dusetzina (ORCID: https://orcid.org/0000-0002-3907-9196)
- Jihye Han
- Grace Castle
Institutions
- Vanderbilt University (US)
Publication Details
- Journal
- JAMA
- Published
- 2026-04-02
- DOI
- https://doi.org/10.1001/jama.2026.2615
- Primary Topic
- Medication Adherence and Compliance
- Type
- article
- Field-Weighted Citation Impact
- 0.00